Effects of mitochondria and o-methoxybenzoylalanine on 3-hydroxyanthranilic acid dioxygenase activity and quinolinic acid synthesis

被引:8
作者
Chiarugi, A [1 ]
Moroni, F [1 ]
机构
[1] Univ Florence, Dipartimento Farmacol Preclin & Clin, I-50134 Florence, Italy
关键词
tryptophan metabolism; quinolinic acid; o-methoxybenzoylalanine; mitochondria; 3-hydroxyanthranilic dioxygenase;
D O I
10.1046/j.1471-4159.1999.0721125.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of o-methoxybenzoylalanine, a selective kynureninase inhibitor, has been proposed with the aim of reducing brain synthesis of quinolinic acid, an excitotoxic tryptophan metabolite. In liver homogenates, however, this compound caused unexpected accumulation of 3-hydroxyanthranilic acid, the product of kynureninase activity and the precursor of quinolinic acid. To explain this observation, we investigated the interaction(s) of o-methoxybenzoylalanine with 3-hydroxyanthranilic acid dioxygenase, the enzyme responsible for quinolinic acid formation, When the purified enzyme or partially purified cytosol preparations were used, o-methoxybenzoylalanine did not affect 3-hydroxyanthranilic acid dioxygenase activity. However, a significant reduction of this enzymatic activity did occur when o-methoxybenzoylalanine was tested in the presence of mitochondria. It is interesting that addition of purified mitochondria to 3-hydroxyanthranilic acid dioxygenase preparations reduced the enzymatic activity and the synthesis of quinolinic acid. In vivo, administration of o-methoxybenzoylalanine significantly reduced quinolinic acid synthesis and content in both blood and brain of mice. Our results suggest that mitochondrial protein(s) interact(s) with soluble 3-hydroxyanthranilic acid dioxygenase and cause(s) modifications in the enzyme resulting in a decrease in its activity. These modifications also allow the enzyme to interact with o-methoxybenzoylalanine, thus leading to a further reduction in quinolinic acid synthesis.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 40 条
[1]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[2]   INHIBITORS OF KYNURENINE HYDROXYLASE AND KYNURENINASE INCREASE CEREBRAL FORMATION OF KYNURENATE AND HAVE SEDATIVE AND ANTICONVULSANT ACTIVITIES [J].
CARPENEDO, R ;
CHIARUGI, A ;
RUSSI, P ;
LOMBARDI, G ;
CARLA, V ;
PELLICCIARI, R ;
MORONI, F ;
MATTOLI, L .
NEUROSCIENCE, 1994, 61 (02) :237-244
[3]  
Cesura AM, 1996, ADV EXP MED BIOL, V398, P477
[4]  
CHIARUGI A, 1995, J NEUROCHEM, V65, P1176
[5]  
Chiarugi A, 1996, J NEUROCHEM, V67, P692
[6]   CYTO-TOXICITY OF 3-HYDROXYKYNURENINE IN A NEURONAL HYBRID CELL-LINE [J].
EASTMAN, CL ;
GUILARTE, TR .
BRAIN RESEARCH, 1989, 495 (02) :225-231
[7]  
FLANAGAN EM, 1995, J NEUROCHEM, V64, P1192
[8]  
FOSTER AC, 1986, J NEUROCHEM, V47, P23
[9]  
GREENAWALT JW, 1980, METHOD ENZYMOL, V45, P310
[10]   QUINOLINIC ACID IN CEREBROSPINAL-FLUID AND SERUM IN HIV-1 INFECTION - RELATIONSHIP TO CLINICAL AND NEUROLOGICAL STATUS [J].
HEYES, MP ;
BREW, BJ ;
MARTIN, A ;
PRICE, RW ;
SALAZAR, AM ;
SIDTIS, JJ ;
YERGEY, JA ;
MOURADIAN, MM ;
SADLER, AE ;
KEILP, J ;
RUBINOW, D ;
MARKEY, SP .
ANNALS OF NEUROLOGY, 1991, 29 (02) :202-209